In the following video, Motley Fool health-care analyst David Williamson takes a look at the dizzying ups and downs of Peregrine Pharmaceuticals (NASDAQ: PPHM). The ongoing saga with the company's leading candidate cancer drug bavituximab has seen shares soar 80% in January, plummet 39% in February, and rally again this month, leaving the stock up 20% overall for the year. David gives investors his take on the drug and where he thinks this wild ride is finally going to end up.
Peregrine's roller coaster ride is as exciting for investors as it is nauseating.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid